Table 5

Summary of Results for Studies I, II, and III (combined results for process replicates a, b, c) for each peptide across sites for inter-site CV, intra-site CV, linear slope and % recovery.

Signature Peptide

Study I

Study II

Study IIIa


Inter- site CV

Intra- site CV

Linear Slope

% Recov.

Inter- site CV

Intra- site CV

Linear Slope

% Recov.

Inter- site CV

Intra- site CV

Linear Slope

% Recov.


APR-AGL

9.20%

3.9-11.2%

1.157

114.5

13.10%

2.0-7.8%

0.575

57.5

13.70%

7.3-45.2%

0.738

79.4

CRP-ESD

5.90%

2.2-5.9%

1.124

118.4

10.50%

3.1-8.4%

0.573

61.4

16.70%

8.5-18.1%

0.439

48.9

CRP-GYS

5.40%

1.4-10.2%

1.324

140.5

5.60%

1.2-6.4%

0.546

56

18.50%

6.6-35.0%

0.159

18.5

HRP-SSD

14.10%

4.0-8.9%

1.198

120.4

5.50%

4.6-7.3%

0.794

82.3

21.90%

8.4-21.4%

0.43

45.7

LEP-IND

12.50%

2.9-10.3%

1.163

119.1

29.50%

2.6-15.3%

0.152

14.9

50.40%

11.7-54.9%

0.242

25.6

MBP-HGF

4.30%

1.7-6.3%

1.161

118.6

9.30%

1.5-7.8%

0.758

77.3

21.80%

7.4-32.8%

0.238

23.8

MBP-YLA

5.10%

2.1-9.3%

1.275

130.3

4.10%

1.5-14.1%

0.806

83.8

N/A

N/A%

N/A

> 1.0

MYO-LFT

4.90%

1.6-5.7%

1.518

154.4

3.80%

2.0-6.3%

1.012

101.3

23.10%

8.9-21.6%

0.504

60.4

PSA-IVG

6.90%

1.3-14.7%

1.658

165.4

5.50%

2.0-11.2%

0.848

81.9

17.20%

7.6-13.7%

0.587

58

PSA-LSE

8.90%

1.2-6.9%

1.098

111.4

5.30%

2.0-4.6%

1.524

151.3

10.30%

7.6-13.7%

0.918

92.7


The CVs increase in distribution between studies I, II, and III as expected with increasing complexity of the three studies. Adapted from Addona, et. al., Nature Biotechnology, 27(7):633-41 (25).

Mani et al. BMC Bioinformatics 2012 13(Suppl 16):S9   doi:10.1186/1471-2105-13-S16-S9

Open Data